Influenza Treatment in Immunocompromised Patients – Phase IV

Treatment of Immunocompromised Patients with Conventional and High Dose Oseltamivir

Protocol Description

The purpose of this multi-center interventional study is to evaluate the efficacy of oseltamivir, also known by the trade name Tamiflu, for the treatment of influenza (flu) in transplant recipients. Researchers are investigating whether a higher dose of the study drug than what is conventionally given can lead to faster resolution of flu in this patient group, whose immune systems are compromised by immunosuppressant treatment.

Study Level: Phase IV

Eligibility Criteria

Subject to certain exclusion criteria, this study is open to transplant recipients (liver, kidney, liver and kidney, allogenic haematopoietic stem cell transplant), who are 1 year of age and older who are shown to be positive for flu by a rapid diagnostic test at baseline.
Males: Age 1 and older
Females: Age 1 and older


Following initial screening examination, participants will be randomly divided into groups that will be given the study drug in either a conventional dose (based on age and weight) or a high dose. Blood testing and other examinations will be conducted during follow up visits.
Visits: Up to 6
Duration: 1 month

Status: Open for Enrollment

Source(s) of Support

Hoffmann-La Roche

Primary Investigator

Marian G. Michaels, MD, MPH

Contact Information

For information, or to enroll, please contact:
Marian G. Michaels, MD, MPH
Noreen Jeffrey, RN